Pathophysiology and Treatment of Systemic Amyloidosis

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2013 Aug 28

PMID 23979488

Citations 44

Authors

Julian D Gillmore

Philip N Hawkins

Affiliations

Soon will be listed here.

Abstract

Amyloid is an abnormal extracellular fibrillar protein deposit in the tissues. In humans, more than 25 different proteins can adopt a fibrillar conformation in vivo that results in the pathognomonic tinctorial property of amyloid (that is, green birefringence when an affected tissue specimen is stained with Congo red dye and viewed by microscopy under cross-polarized light). Amyloid deposition is associated with disturbance of organ function and causes a wide variety of clinical syndromes that are classified according to the respective fibril protein precursor. Systemic amyloidosis, in which amyloid deposits are widespread and typically accumulate gradually, continues to be fatal and is responsible for about one in 1,500 deaths per year in the UK. Advances in our understanding of the pathogenesis of systemic amyloidosis have resulted in the identification of new therapeutic targets, and several drugs with novel mechanisms of action are currently under development. Meanwhile, an increased awareness of amyloidosis coupled with enhancements to existing diagnostic techniques and therapeutic strategies have already resulted in better outcomes for patients with the disease.

Citing Articles

Detection of cardiac amyloidosis using machine learning on routine echocardiographic measurements.

Chang R, Chiu I, Tacon P, Abiragi M, Cao L, Hong G Open Heart. 2024; 11(2.

PMID: 39694574 PMC: 11667434. DOI: 10.1136/openhrt-2024-002884.

A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.

Senigarapu S, Driscoll J Front Med (Lausanne). 2024; 11:1477988.

PMID: 39540049 PMC: 11557331. DOI: 10.3389/fmed.2024.1477988.

Thyroid Gland Diffuse Lipomatosis: A Case Study and Comprehensive Literature Review.

Emmanouilidou A, Karanikas M, Pazaitou-Panayiotou K, Michalopoulos N J Clin Med. 2024; 13(21).

PMID: 39518515 PMC: 11547090. DOI: 10.3390/jcm13216376.

Familial occurrences of cardiac wild-type transthyretin amyloidosis: a case series.

Westin O, Clemmensen T, Hansen A, Gustafsson F, Hvitfeldt Poulsen S Eur Heart J Case Rep. 2024; 8(5):ytae199.

PMID: 38765770 PMC: 11099943. DOI: 10.1093/ehjcr/ytae199.

Deactivation of the Unfolded Protein Response Aggravated Renal AA Amyloidosis in HSF1 Deficiency Mice.

Liu W, Xia S, Yao F, Huo J, Qian J, Liu X Mol Cell Biol. 2024; 44(5):165-177.

PMID: 38758542 PMC: 11123510. DOI: 10.1080/10985549.2024.2347937.

References

Rajkumar S, Gertz M, Kyle R . Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998; 82(8):1501-5. View

Gillmore J, Goodman H, Lachmann H, Offer M, Wechalekar A, Joshi J . Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2005; 107(3):1227-9. DOI: 10.1182/blood-2005-08-3253. View

Hartley D, Walsh D, Ye C, Diehl T, Vasquez S, Vassilev P . Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999; 19(20):8876-84. PMC: 6782787. View

Soni A, Lelorier P . Sudden death in nondilated cardiomyopathies: pathophysiology and prevention. Curr Heart Fail Rep. 2005; 2(3):118-23. DOI: 10.1007/s11897-005-0019-x. View

Rocken C, Schwotzer E, Linke R, Saeger W . The classification of amyloid deposits in clinicopathological practice. Histopathology. 1996; 29(4):325-35. DOI: 10.1111/j.1365-2559.1996.tb01416.x. View

Cibeira M, Sanchorawala V, Seldin D, Quillen K, Berk J, Dember L . Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011; 118(16):4346-52. PMC: 3204906. DOI: 10.1182/blood-2011-01-330738. View

Venner C, Lane T, Foard D, Rannigan L, Gibbs S, Pinney J . Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012; 119(19):4387-90. DOI: 10.1182/blood-2011-10-388462. View

Gillmore J, Lachmann H, Rowczenio D, Gilbertson J, Zeng C, Liu Z . Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2008; 20(2):444-51. PMC: 2637055. DOI: 10.1681/ASN.2008060614. View

Traut M, Haufe C, Eismann U, Deppisch R, Stein G, Wolf G . Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. Blood Purif. 2007; 25(5-6):432-40. DOI: 10.1159/000110069. View

10.

Lovat L, Persey M, Madhoo S, Pepys M, Hawkins P . The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998; 42(5):727-34. PMC: 1727098. DOI: 10.1136/gut.42.5.727. View

11.

Valleix S, Gillmore J, Bridoux F, Mangione P, Dogan A, Nedelec B . Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med. 2012; 366(24):2276-83. DOI: 10.1056/NEJMoa1201356. View

12.

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

13.

Falk R . Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112(13):2047-60. DOI: 10.1161/CIRCULATIONAHA.104.489187. View

14.

Panizo N, Rivera F, Lopez-Gomez J . Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest. 2013; 43(8):767-73. DOI: 10.1111/eci.12097. View

15.

Maceira A, Joshi J, Prasad S, Moon J, Perugini E, Harding I . Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111(2):186-93. DOI: 10.1161/01.CIR.0000152819.97857.9D. View

16.

Greenwald J, Riek R . Biology of amyloid: structure, function, and regulation. Structure. 2010; 18(10):1244-60. DOI: 10.1016/j.str.2010.08.009. View

17.

Nelson S, Hawkins P, Richardson S, LAVENDER J, Sethi D, Gower P . Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet. 1991; 338(8763):335-9. DOI: 10.1016/0140-6736(91)90478-8. View

18.

Kristen A, Dengler T, Hegenbart U, Schonland S, Goldschmidt H, Sack F . Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008; 5(2):235-40. DOI: 10.1016/j.hrthm.2007.10.016. View

19.

Tan S, Irish A, Winearls C, Brown E, Gower P, Clutterbuck E . Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int. 1996; 50(1):282-9. DOI: 10.1038/ki.1996.313. View

20.

Obici L, Perfetti V, Palladini G, Moratti R, Merlini G . Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005; 1753(1):11-22. DOI: 10.1016/j.bbapap.2005.08.014. View